Life Sciences Tools and Services
Company Overview of Antitope Ltd
Antitope Ltd., a biotechnology research company, develops non-immunogenic protein therapeutics. The company specializes in immunogenicity testing and the engineering of therapeutic antibodies/proteins with reduced immunogenicity. It offers EpiScreen, an ex vivo human T cell assay technology for predicting the immunogenicity of biologics or for identifying T cell epitopes within the sequences of biologics; Composite Human Antibody technology for generating humanized antibodies devoid of human T cell epitopes; and Composite Protein technology for generating therapeutic proteins devoid of human T cell epitopes. The company also provides pANT Vector System, an expression system to enhance expres...
Babraham Research Campus
Cambridge, CB22 3AT
Founded in 2004
Key Executives for Antitope Ltd
Chief Executive Officer and Director
Co-Founder, Chief Scientific Officer and Director
Vice President of Business Development
Compensation as of Fiscal Year 2014.
Antitope Ltd Key Developments
Antitope, INSERM and Baylor Institute to Collaborate to Produce Manufacturing Cell Lines for Two Novel Vaccines for HIV
Jan 13 15
Antitope Limited announced that it has extended its relationship with INSERM, ANRS and the Baylor Institute for Immunology Research. INSERM-ANRS and the BIIR have developed innovative approaches for HIV vaccines targeting HIV antigens to dendritic cells (DC) using monoclonal antibodies fused to HIV antigens. Extensive preclinical data has demonstrated the high immunogenicity of the candidate vaccines. Antitope will produce cell lines for GMP manufacture of two anti-CD40-HIV fusion proteins that INSERM-ANRS and BIIR are developing as potential therapeutic and prophylactic vaccines to treat HIV. The cell lines will be produced using Antitope’s Composite CHO™ technology. The antibody component of the fusion proteins has previously been humanized by Antitope using its Composite Human Antibody™ technology. Phase I and Phase II clinical trials will be conducted in France to test the immunogenicity and efficacy of these DC-targeting vaccines developed by INSERM-ANRS in partnership with the BIIR.
Antitope Limited and University College London Enter into Research & Licence Agreement for Generation of Fully Humanized Antibodies
Aug 21 14
Abzena plc announced that its wholly-owned subsidiary Antitope Limited and University College London (UCL) will collaborate to humanize an anti-LRG1 antibody as part of a MRC-funded translational research and product development programme being undertaken by the UCL Institute of Ophthalmology. The collaboration is supported by UCL Business PLC (UCLB), UCL's wholly owned technology transfer company, which provided initial Proof of Concept funding and holds the patents to the LRG1 technologies. LRG1 (leucine-rich alpha-2-glycoprotein 1) was identified by researchers at UCL to promote the growth of blood vessels (a process known as angiogenesis). Antitope will produce a range of fully humanized antibodies using its Composite Human Antibody technology that are designed to bind to and inhibit the function of LRG1. UCL will select a lead antibody for further evaluation as a potential therapeutic product for the treatment of age-related macular degeneration (AMD). UCLB is continuing to support development of this technology and is currently seeking commercial partners to take it to market.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries